Compare Amgen, Inc. (AMGN) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Huntington Bancshares Incorporated — how do they compare? Amgen, Inc. trades at $355.98 (market cap $196.12B), while Huntington Bancshares Incorporated trades at $17.8 (market cap $36.22B). The key difference: Amgen, Inc. is far larger — about 5.4× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| AMGN | HBAN | |
|---|---|---|
Market Cap | $196.12B | $36.22B |
Sector | Health | Financials |
52-Week High | $388.16 | $19.27 |
52-Week Low | $271.18 | $15.02 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HBAN trades at $17.87, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.25. Recent Q1 2026 earnings beat expectations with EPS of $0.26, and revenue for 2025 grew to $8.13B. The company maintains a solid net income margin of 25.13% and a P/E ratio of 13.75, indicating reasonable valuation. News highlights include expansion in Texas and a recent dividend payment, supporting positive sentiment.
The outlook for HBAN is positive, with growth driven by strategic acquisitions and organic loan expansion, though risks include integration challenges and competitive pressures in regional banking. Analysts are predominantly bullish, with 49% recommending buy, suggesting potential upside from current levels if earnings targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
